SK50497A3 - Use of £r-(z)|-alpha-(methoxyimino)-alpha-(1-azabicyclo £2.2.2| oct-3-yl) acetonitrile and pharmaceutical composition containing same - Google Patents

Use of £r-(z)|-alpha-(methoxyimino)-alpha-(1-azabicyclo £2.2.2| oct-3-yl) acetonitrile and pharmaceutical composition containing same Download PDF

Info

Publication number
SK50497A3
SK50497A3 SK504-97A SK50497A SK50497A3 SK 50497 A3 SK50497 A3 SK 50497A3 SK 50497 A SK50497 A SK 50497A SK 50497 A3 SK50497 A3 SK 50497A3
Authority
SK
Slovakia
Prior art keywords
disease
pharmaceutically acceptable
alzheimer
acetonitrile
compound
Prior art date
Application number
SK504-97A
Other languages
English (en)
Slovak (sk)
Inventor
Roger E Markwell
Julie Hawkins
Carol W Gray
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of SK50497A3 publication Critical patent/SK50497A3/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SK504-97A 1994-10-25 1995-10-17 Use of £r-(z)|-alpha-(methoxyimino)-alpha-(1-azabicyclo £2.2.2| oct-3-yl) acetonitrile and pharmaceutical composition containing same SK50497A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9421472A GB9421472D0 (en) 1994-10-25 1994-10-25 Novel methods
PCT/EP1995/004082 WO1996012486A1 (en) 1994-10-25 1995-10-17 Use of [r-(z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo [2.2.2] oct-3-yl) acetonitrile to reduce amyloid beta a4 formation in alzheimer's disease

Publications (1)

Publication Number Publication Date
SK50497A3 true SK50497A3 (en) 1997-09-10

Family

ID=10763350

Family Applications (1)

Application Number Title Priority Date Filing Date
SK504-97A SK50497A3 (en) 1994-10-25 1995-10-17 Use of £r-(z)|-alpha-(methoxyimino)-alpha-(1-azabicyclo £2.2.2| oct-3-yl) acetonitrile and pharmaceutical composition containing same

Country Status (22)

Country Link
US (1) US5891887A (cs)
EP (1) EP0786998B1 (cs)
JP (1) JPH10509697A (cs)
KR (1) KR100393365B1 (cs)
CN (1) CN1085529C (cs)
AT (1) ATE214926T1 (cs)
AU (1) AU698695B2 (cs)
BG (1) BG101500A (cs)
BR (1) BR9509433A (cs)
CZ (1) CZ287370B6 (cs)
DE (1) DE69526102T2 (cs)
DK (1) DK0786998T3 (cs)
ES (1) ES2173977T3 (cs)
GB (1) GB9421472D0 (cs)
HK (1) HK1002057A1 (cs)
HU (1) HUT77007A (cs)
NO (1) NO312055B1 (cs)
NZ (1) NZ295155A (cs)
PT (1) PT786998E (cs)
SK (1) SK50497A3 (cs)
WO (1) WO1996012486A1 (cs)
ZA (1) ZA958946B (cs)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU751607B2 (en) * 1995-07-29 2002-08-22 Smithkline Beecham Plc Method of treatment of dementia
GB9619074D0 (en) * 1996-09-12 1996-10-23 Smithkline Beecham Plc Composition
DE19641180A1 (de) * 1996-09-24 1998-03-26 Schering Ag Verfahren zur Darstellung von APP-Sekretase Modulation und deren Verwendung als Mittel zur Behandlung der Alzheimer'schen Erkrankung
CA2323177A1 (en) * 1998-03-11 1999-09-16 Susan Marie Milosovich Composition
GB9815383D0 (en) * 1998-07-15 1998-09-16 Smithkline Beecham Plc Novel method of treatment
US6245884B1 (en) * 1998-10-16 2001-06-12 Vivian Y. H. Hook Secretases related to alzheimer's dementia
US7816149B2 (en) * 2004-03-29 2010-10-19 Applied Photonics Worldwide, Inc. Nanobioprocessor for protein and cell therapy
GB0428170D0 (en) * 2004-12-23 2005-01-26 Biopartners Ltd Mono and Combination Therapy

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0392803T3 (da) * 1989-04-13 2004-10-18 Beecham Group Plc Hidtil ukendte forbindelser
US5385915A (en) * 1990-05-16 1995-01-31 The Rockefeller University Treatment of amyloidosis associated with Alzheimer disease using modulators of protein phosphorylation
US5242932A (en) * 1991-12-17 1993-09-07 The Rockefeller University Treatment of amyloidosis associated with alzheimer disease
JPH0725786A (ja) * 1990-05-16 1995-01-27 Univ Rockefeller アルツハイマー病を伴うアミロイドーシスの治療
MX9300875A (es) * 1992-02-20 1993-08-31 Smithkline Beecham Plc Procedimiento para la preparacion de compuestos azabiciclicos.
WO1994009370A1 (en) * 1992-10-09 1994-04-28 Massachusetts Institute Of Technology Release of alzheimer amyloid precursor stimulated by activation of muscarinic acetylcholine receptors
GB9409705D0 (en) * 1994-05-14 1994-07-06 Smithkline Beecham Plc Novel compounds

Also Published As

Publication number Publication date
NO312055B1 (no) 2002-03-11
EP0786998A1 (en) 1997-08-06
NO971899D0 (no) 1997-04-24
DE69526102T2 (de) 2002-10-31
DK0786998T3 (da) 2002-07-15
HK1002057A1 (en) 1998-07-31
CZ287370B6 (en) 2000-11-15
AU698695B2 (en) 1998-11-05
BR9509433A (pt) 1997-09-16
MX9703077A (es) 1997-07-31
CN1085529C (zh) 2002-05-29
CN1170365A (zh) 1998-01-14
AU3843195A (en) 1996-05-15
GB9421472D0 (en) 1994-12-07
WO1996012486A1 (en) 1996-05-02
HUT77007A (hu) 1998-03-02
NO971899L (no) 1997-04-24
ATE214926T1 (de) 2002-04-15
NZ295155A (en) 2000-07-28
DE69526102D1 (de) 2002-05-02
ZA958946B (en) 1996-08-20
KR970706816A (ko) 1997-12-01
KR100393365B1 (ko) 2003-12-18
JPH10509697A (ja) 1998-09-22
EP0786998B1 (en) 2002-03-27
CZ125197A3 (en) 1997-07-16
US5891887A (en) 1999-04-06
BG101500A (en) 1998-01-30
PT786998E (pt) 2002-09-30
ES2173977T3 (es) 2002-11-01

Similar Documents

Publication Publication Date Title
Solomon et al. Induction in mice of human light-chain-associated amyloidosis.
EP1379269B1 (en) Adenosine a2a receptor antagonists combined with neurotrophic activity compounds in the treatment of parkinson's disease
US20010006972A1 (en) Nk-1 receptor antagonists for the treatment of symptoms of irritable bowel syndrome
Nagasawa et al. . beta.-Substituted cysteines as sequestering agents for ethanol-derived acetaldehyde in vivo
Nunzi et al. Immunopathological studies on alopecia areata
Goldstein et al. Binding interactions of ergot alkaloids with monoaminergic receptors in the brain
SK50497A3 (en) Use of £r-(z)|-alpha-(methoxyimino)-alpha-(1-azabicyclo £2.2.2| oct-3-yl) acetonitrile and pharmaceutical composition containing same
EP2535049A1 (en) Tadalafil for the treatment of dementia
EP0873753A1 (en) Use of NK-1 receptor antagonists for the manufacture of a medicament in the treatment of symptoms of irritable bowel syndrome
Syvälahti et al. Effects of antiparkinsonian drugs on muscarinic receptor binding in rat brain, heart and lung
EP0557290A1 (en) Treatment of aids dementia, myelopathy, peripheral neuropathy, and vision loss
KR20230096003A (ko) 만성 ssri 레지멘 후 실로시빈에 대한 민감도를 증가시키기 위한 벤조디아제핀의 사용
IE912237A1 (en) Pharmaceutical preparations
KR20000035446A (ko) 세포접착분자 발현억제제
Syvälahti et al. Interaction of psychotropic drugs with brain muscarinic cholinoceptors: similarities of biperiden with pirenzepine in receptor binding properties
Rius et al. Acute ethanol effect on calcium antagonist binding in rat brain
US6544565B2 (en) Use of Valeriana for the treatment of Restless Leg Syndrome and related disorders
WO2005013910A2 (en) Cholinergic modulation of microglial activation via alpha-7 nicotinic receptors
Arranz et al. Characterization of the 5-HT 4 binding site in human brain
MXPA97003077A (en) Use of acetonitrila [r- (z)] - alpha- (metoximino) -alfa- (1-azabiciclo [2.2.2.] oct-3-ilo) to reduce the formation of beta a4 amylide in alzhei's disease
AU758936B2 (en) Method of treatment
Viglione et al. Lambert–Eaton syndrome: antigen–antibody interaction and calcium current inhibition in chromaffin cells
DePetrillo Effects of chronic alcohol use and age on human lymphocyte protein kinase C activity
TERLECKYJ et al. Interactions at Dopamine Receptors’
Karton et al. Rachel Haring", David Gurwitz"*, Jacob Bargº", Ronit Pinkas-Kramarski", Eliahu Heldman", Zipora Pittel', Ada Wengier", Haim Meshulam", Daniele Marciano"